首頁 > 市場調查報告書 > 醫療設備

泌尿科

市場調查報告書

商品編碼

1601793

女性壓力性尿失禁治療設備市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品類型、最終用戶、地區和競爭細分，2019-2029F

Female Stress Urinary Incontinence Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End-user, By Region and Competition, 2019-2029F

出版日期: 2024年11月30日 | 出版商:

TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球女性壓力性尿失禁治療設備市場價值為7.7218億美元，預計2029年將達到11.0777億美元，預測期內複合年成長率為6.34%。

市場概況
預測期	2025-2029
2023 年市場規模	77218萬美元
2029 年市場規模	110777萬美元
2024-2029 年複合年成長率	6.34%
成長最快的細分市場	尿道吊帶
最大的市場	北美洲

由於女性壓力性尿失禁 (SUI) 盛行率不斷上升、醫療技術的進步以及對可用治療方案的認知不斷提高，全球女性壓力性尿失禁 (SUI) 治療設備市場正在大幅成長。壓力性尿失禁是一種因咳嗽、打噴嚏或運動等體力活動導致不自主尿液漏出的疾病，會嚴重影響生活品質。由於老化、肥胖和生育等因素，發病率不斷上升，推動了對有效治療解決方案的需求。市面上的主要設備包括陰道吊帶、人工尿道括約肌和電刺激設備。可調節和先進吊帶的新興創新進一步改善了患者的治療效果，鼓勵了採用。電刺激裝置作為非手術替代方案越來越受到關注，吸引了尋求保守治療選擇的女性。

主要參與者正大力投資研發，旨在推出創新的、以患者為中心的解決方案。與醫療保健提供者的合作夥伴關係和策略性收購正在塑造市場動態。然而，設備相關併發症、手術介入的高成本以及資源匱乏地區獲得先進治療的機會有限等挑戰構成了障礙。在技術進步、診斷率提高以及改善全球女性健康的努力的支撐下，該市場有望顯著成長。這條軌跡強調了治療設備在提高受壓力性尿失禁影響的女性的生活品質方面的關鍵作用。

主要市場促進因素

女性壓力性尿失禁的盛行率不斷上升

SUI 盛行率的上升增加了對各種治療設備的需求。其中包括陰道吊帶、骨盆底電刺激系統和尿道填充劑，它們共同提供不同患者需求的手術和非手術解決方案。醫療技術的進步也引入了微創和門診手術，進一步吸引了尋求有效且方便的治療選擇的患者。一項干預性研究（ClinicalTrials.gov：NCT03978741）評估了 Yoni.Fit 對於符合特定診斷標準的 18 歲及以上女性臨時控制壓力性尿失禁 (SUI) 的安全性和有效性。共有 58 位患者被隨機分配使用 Yoni.Fit 或比較設備。主要終點是第 21 天的反應率，定義為與基線相比，12 小時墊重量平均減少 50%。結果顯示，更多使用 Yoni.Fit 的患者實現了具有臨床意義的護墊重量減輕（53% 對比 23.3%；P = 0.013）。此外，96.3% 的 Yoni.Fit 使用者的 SUI 發作次數減少了 50% 以上，而對照組為 27.2%（P< 0.001）。 Yoni.Fit 組中更多的患者報告「明顯改善」或更好（P = 0.001）。最常見的不良事件是陰道不適，沒有嚴重不良事件的通報。此外，公眾意識活動和健康教育計劃正在闡明 SUI 及其治療方法，減少恥辱並鼓勵更多女性尋求專業幫助。這種日益成長的認知，加上創新治療設備的出現，使市場進一步擴大，滿足了越來越多受影響人群的需求。

微創治療技術的進步

微創治療技術的進步已成為全球女性壓力性尿失禁（SUI）治療設備市場成長的關鍵驅動力。傳統的外科手術雖然有效，但通常需要較長的恢復時間，並且出現感染和組織損傷等併發症的風險較高。現代創新，例如無張力陰道吊帶和經閉孔膠帶系統，透過提供侵入性顯著降低的高效解決方案，改變了這些手術。這些設備旨在提供更快的恢復時間、減少術後疼痛並降低併發症的風險，從而提高患者的舒適度和治療效果。

這些處理方法最顯著的進步之一在於所使用的材料。現代吊帶裝置現在採用輕質、生物相容性網狀材料，可提供耐用性，同時最大限度地減少組織刺激。材料的這種演變提高了患者滿意度，減少了長期併發症，並有助於提高整體成功率。這些創新也使程序對醫療保健提供者更具吸引力，使他們能夠提供量身定做的、針對患者的解決方案。同時，非手術治療替代方案也取得了顯著進展。例如，電刺激設備現在具有更精確的瞄準機制，可以有效增強骨盆底肌肉，而無需侵入性手術。這些技術對於尋求強度較低的治療方案的女性或禁忌手術的女性特別有益。

醫療器材公司對研發的持續關注確保了持續的創新。這些努力不僅擴大了治療選擇的範圍，而且還提高了設備的安全性、有效性和可負擔性。數位健康技術的整合，例如遠端監控和基於應用程式的設備使用指導，使治療變得更加方便用戶使用和方便。由於這些技術進步同時滿足了手術和非手術需求，因此提高了患者和醫療保健提供者的採用率，最終促進了全球女性 SUI 治療設備市場的成長。

對 SUI 治療的認知與接受度不斷提高

人們對壓力性尿失禁（SUI）治療的認知和接受度不斷提高，已成為推動全球市場成長的重要因素。從歷史上看，社會恥辱和對 SUI 的了解有限，使許多女性不願尋求專業幫助，從而導致這種情況得不到治療並影響了她們的生活品質。然而，多年來，醫療保健提供者、非政府組織和設備製造商的共同努力已經顯著改變了這種說法。教育活動在減少與 SUI 相關的恥辱方面發揮了至關重要的作用。這些舉措強調了這種疾病的流行程度、其對日常生活的影響以及及時尋求治療的重要性。透過使有關 SUI 的討論正常化，這些努力使女性能夠認知到這種情況是一個可以控制的醫療問題，而不是個人的失敗。醫療保健提供者越來越強調早期介入的好處，例如預防併發症和改善生活品質，進一步鼓勵女性尋求治療。

數位平台的興起也徹底改變了 SUI 資訊的取得方式。包括網站、社交媒體和遠端諮詢服務在內的線上資源使女性更容易了解自己的病情並探索可用的治療方法。設備製造商和醫療保健組織提供的互動式工具和教育內容正在彌合知識差距，使患者能夠做出明智的決策。此外，社會對女性健康的態度也發生了變化，促進了對 SUI 等問題的公開討論。這種轉變，加上健康素養的提高，導致尋求專家諮詢和探索從微創外科手術到非侵入性治療等治療方案的女性人數激增。

主要市場挑戰

先進處理設備成本高

市場競爭激烈，缺乏差異化

主要市場趨勢

增加研發投資

擴大新興市場的醫療保健基礎設施

細分市場洞察

產品類型見解

區域洞察

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 772.18 Million
Market Size 2029	USD 1107.77 Million
CAGR 2024-2029	6.34%
Fastest Growing Segment	Urethral Slings
Largest Market	North America

The Global Female Stress Urinary Incontinence (SUI) Treatment Devices Market is witnessing substantial growth, driven by the increasing prevalence of SUI among women, advances in medical technologies, and growing awareness of available treatment options. Stress urinary incontinence, a condition characterized by involuntary urine leakage due to physical activities such as coughing, sneezing, or exercising, significantly impacts quality of life. The rising incidence, attributed to factors such as aging, obesity, and childbirth, is propelling the demand for effective treatment solutions. Key devices in the market include vaginal slings, artificial urinary sphincters, and electrical stimulation devices.Vaginal slings, particularly minimally invasive tension-free procedures, dominate the market due to their high success rates and shorter recovery times. Emerging innovations in adjustable and advanced slings have further enhanced patient outcomes, encouraging adoption. Electrical stimulation devices are gaining traction as non-surgical alternatives, appealing to women seeking conservative treatment options.

Key players are heavily investing in research and development, aiming to introduce innovative, patient-centric solutions. Partnerships with healthcare providers and strategic acquisitions are shaping market dynamics. However, challenges such as device-related complications, high costs of surgical interventions, and limited access to advanced treatments in low-resource settings pose barriers. The market is poised for significant growth, underpinned by technological advancements, increased diagnosis rates, and efforts to improve women's health worldwide. This trajectory underscores the critical role of treatment devices in enhancing the quality of life for women affected by stress urinary incontinence.

Key Market Drivers

Rising Prevalence of Stress Urinary Incontinence Among Women

The rising prevalence of stress urinary incontinence (SUI) among women globally is a critical factor driving the market's growth. SUI, characterized by involuntary leakage of urine during physical activities such as coughing, sneezing, or exercising, is often caused by the weakening of pelvic floor muscles and urethral support. Key contributing factors include aging, childbirth, menopause, obesity, and chronic medical conditions. With an increasingly aging population, particularly in developed nations, the number of women affected by SUI is steadily rising. Interestingly, the condition is no longer confined to older demographics. Sedentary lifestyles, obesity, and high levels of physical strain are contributing to a noticeable increase in cases among younger women. This shift highlights the condition's evolving dynamics and underscores the growing need for effective treatment options. Women experiencing SUI often face reduced quality of life, embarrassment, and potential social isolation, leading to greater awareness and a proactive approach to seeking medical solutions.

The heightened prevalence of SUI has bolstered demand for a variety of treatment devices. These include vaginal slings, pelvic floor electrical stimulation systems, and urethral bulking agents, which collectively offer surgical and non-surgical solutions tailored to different patient needs. Advancements in medical technology have also introduced minimally invasive and outpatient procedures, further appealing to patients seeking effective yet convenient treatment options. An interventional study (ClinicalTrials.gov: NCT03978741) assessed the safety and efficacy of Yoni.Fit for temporarily managing stress urinary incontinence (SUI) in women aged 18 and older, who met specific diagnostic criteria. A total of 58 patients were randomized to use Yoni.Fit or a comparator device. The primary endpoint was a responder rate at day 21, defined as a 50% reduction in mean 12-hour pad weight compared to baseline. Results showed significantly more patients using Yoni.Fit achieved clinically meaningful reductions in pad weight (53% vs. 23.3%; P = 0.013). Additionally, 96.3% of Yoni.Fit users experienced a >50% reduction in SUI episodes, compared to 27.2% in the comparator group (P < 0.001). More patients in the Yoni.Fit group reported being "much improved" or better (P = 0.001). The most common adverse event was vaginal discomfort, with no serious adverse events reported. In addition, public awareness campaigns and health education programs are shedding light on SUI and its treatment, reducing stigma and encouraging more women to seek professional help. This growing recognition, coupled with the availability of innovative treatment devices, positions the market to expand further as it addresses the needs of an increasingly affected population.

Advancements in Minimally Invasive Treatment Technologies

Advancements in minimally invasive treatment technologies have become a pivotal driver in the growth of the global female stress urinary incontinence (SUI) treatment devices market. Traditional surgical interventions, while effective, often involve extensive recovery times and carry higher risks of complications such as infections and tissue damage. Modern innovations, such as tension-free vaginal slings and transobturator tape systems, have transformed these procedures by providing highly effective solutions that are significantly less invasive. These devices are designed to offer faster recovery periods, reduced postoperative pain, and lower risks of complications, thereby enhancing patient comfort and outcomes.

One of the most notable advancements in these treatments lies in the materials used. Modern sling devices now utilize lightweight, biocompatible meshes that provide durability while minimizing tissue irritation. This evolution in materials has improved patient satisfaction, reduced long-term complications, and contributed to better overall success rates. These innovations have also made procedures more appealing to healthcare providers, enabling them to offer tailored, patient-specific solutions. In parallel, non-surgical treatment alternatives have also advanced significantly. Electrical stimulation devices, for instance, now feature more precise targeting mechanisms that strengthen pelvic floor muscles effectively without invasive procedures. These technologies have been particularly beneficial for women seeking less intensive treatment options or for those contraindicated for surgery.

The continued focus on research and development by medical device companies ensures a consistent pipeline of innovations. These efforts have not only expanded the range of treatment options but have also enhanced the safety, efficacy, and affordability of devices. The integration of digital health technologies, such as remote monitoring and app-based guidance for device use, has made treatments more user-friendly and accessible. As these technological advancements address both surgical and non-surgical needs, they are driving higher adoption rates among patients and healthcare providers alike, ultimately fostering growth in the global female SUI treatment devices market.

Growing Awareness and Acceptance of SUI Treatments

The growing awareness and acceptance of stress urinary incontinence (SUI) treatments have become a vital factor in driving the global market's growth. Historically, social stigma and limited knowledge about SUI discouraged many women from seeking professional help, leaving the condition untreated and impacting their quality of life. However, over the years, concerted efforts by healthcare providers, non-governmental organizations, and device manufacturers have significantly shifted this narrative. Educational campaigns have played a crucial role in reducing the stigma associated with SUI. These initiatives highlight the prevalence of the condition, its impact on daily life, and the importance of seeking timely treatment. By normalizing discussions around SUI, these efforts have empowered women to recognize the condition as a manageable medical issue rather than a personal failing. Healthcare providers have increasingly emphasized the benefits of early intervention, such as preventing complications and improving quality of life, further encouraging women to seek treatment.

The rise of digital platforms has also revolutionized access to information about SUI. Online resources, including websites, social media, and teleconsultation services, have made it easier for women to learn about their condition and explore available treatments. Interactive tools and educational content provided by device manufacturers and healthcare organizations are bridging the knowledge gap, enabling informed decision-making among patients. Additionally, societal attitudes toward women's health have evolved, promoting open discussions about issues like SUI. This shift, coupled with improved health literacy, has led to a surge in the number of women seeking consultations with specialists and exploring treatment options, ranging from minimally invasive surgical procedures to non-invasive therapies.

Key Market Challenges

High Costs of Advanced Treatment Devices

The high costs associated with advanced female stress urinary incontinence (SUI) treatment devices pose a significant barrier to market growth. Devices such as electrical stimulation units and biofeedback systems are lauded for their effectiveness and convenience, but their premium pricing makes them inaccessible to a large segment of the population, particularly in low- and middle-income regions. Many patients in these areas face economic constraints that prevent them from considering such high-cost solutions. In developed markets, the issue is compounded by the limited coverage offered by health insurance providers. Non-surgical treatments are often considered elective, leading to partial reimbursement or outright exclusion from insurance plans, further increasing out-of-pocket expenses for patients.

Healthcare providers are also impacted by the high costs of these devices. Budget restrictions, particularly in public healthcare institutions or smaller private clinics, deter providers from investing in advanced equipment, limiting the availability of these treatments to patients. This financial hurdle restricts market penetration, as even highly innovative products struggle to achieve widespread adoption due to their prohibitive costs. Manufacturers face the dual challenge of innovating while maintaining affordability, which is critical for expanding their consumer base. Without addressing these cost-related concerns, the adoption of advanced female SUI treatment devices may remain confined to affluent regions, stalling global market growth and leaving many patients without access to effective care.

Intense Market Competition and Lack of Differentiation

The global female stress urinary incontinence (SUI) treatment devices market is facing intense competition, with a growing number of manufacturers offering similar products. This saturation creates significant challenges for companies trying to stand out in a crowded marketplace. Many devices targeting the same patient demographics provide comparable functionalities, which has led to price wars, where manufacturers reduce their prices to attract customers. While this may benefit patients in terms of affordability, it erodes profit margins and limits the ability of manufacturers to reinvest in product innovation. Smaller or newer companies often find it particularly difficult to compete against well-established players with greater resources for marketing, distribution, and research and development. These larger companies can leverage their brand recognition, extensive distribution networks, and financial strength to dominate the market, leaving less room for smaller firms to grow. The competition also limits the ability of newer players to achieve economies of scale, further hindering their ability to offer competitive pricing.

The lack of significant differentiation between treatment devices further complicates purchasing decisions for healthcare providers and patients. Many products in the market offer similar therapeutic benefits, and without clear distinctions in terms of features, effectiveness, or usability, both patients and providers may struggle to select the most appropriate device. This confusion can delay the adoption of innovative products, impacting overall market growth and reducing the pace at which advancements reach the patient population.

Key Market Trends

Increasing Investments in Research and Development

Increasing investments in research and development (R&D) are driving significant advancements in the global market for stress urinary incontinence (SUI) treatment devices. Medical device companies are allocating substantial resources to innovate and improve existing technologies, focusing on enhancing patient outcomes and addressing unmet clinical needs. This commitment to R&D is fueling the development of devices that are safer, more effective, and tailored to individual patient requirements. For instance, The study titled "Randomized Trial of Mechanotherapy for the Treatment of Stress Urinary Incontinence in Women" validates the efficacy of the FDA-cleared Flyte device. The findings show significant improvements in women with stress urinary incontinence (SUI) and weakened pelvic floor muscles. Conducted as a double-blind, controlled trial with 119 participants, it is one of the largest studies examining in-home SUI treatments. Notably, 71% of participants achieved dryness or near dryness during the treatment period, with lasting improvements in quality of life over two years. This research builds on prior studies from the Arctic University of Norway, where Flyte demonstrated a high success rate in addressing long-term SUI symptoms, often reducing the need for surgical intervention.

A key area of focus in R&D is the improvement of sling materials used in surgical treatments. Innovations in biocompatible, lightweight meshes are reducing complications such as infection and tissue erosion while improving patient comfort and long-term outcomes. Simultaneously, advancements in electrical stimulation devices are enabling more precise targeting of pelvic floor muscles, leading to improved treatment efficacy and increased patient satisfaction. These technological breakthroughs are critical in expanding non-surgical options, particularly for women seeking minimally invasive solutions.

Collaborative efforts between medical device manufacturers, academic institutions, and healthcare providers are further accelerating innovation. These partnerships facilitate the development of next-generation devices by combining clinical insights with engineering expertise. Customizable solutions tailored to diverse patient anatomies and conditions are emerging as a direct result of these joint initiatives, making treatment options more inclusive and effective. R&D investments are also addressing safety concerns and reducing device-related complications, which are pivotal factors influencing patient and provider choices. By improving the safety profile of treatment devices, companies are fostering greater trust and adoption among healthcare professionals and patients alike. The drive for regulatory approvals of advanced devices is enhancing market penetration across regions. Once approved, these innovations not only strengthen the competitive position of manufacturers but also provide patients with access to cutting-edge solutions. This steady pipeline of new products ensures the market remains dynamic, responsive, and aligned with the evolving needs of women affected by SUI, further propelling its growth globally.

Expanding Healthcare Infrastructure in Emerging Markets

The expansion of healthcare infrastructure in emerging markets such as Asia-Pacific, Latin America, and the Middle East is significantly driving the demand for stress urinary incontinence (SUI) treatment devices. Governments and private sector entities in these regions are investing heavily in modernizing healthcare systems, resulting in improved access to advanced diagnostic and therapeutic solutions. These efforts are bridging the gap between healthcare facilities in urban and rural areas, allowing more women to seek timely and effective treatment for SUI.

One key factor contributing to this growth is the rising awareness of SUI and its impact on quality of life. Enhanced healthcare outreach programs, often supported by public-private partnerships, are educating women about SUI and the importance of early intervention. Simultaneously, physician training initiatives are equipping healthcare providers with the knowledge and skills to recommend and administer advanced treatment options. These efforts are normalizing discussions around SUI, reducing stigma, and encouraging women to seek professional care. The economic transformation in countries like China, India, and Brazil is another critical driver. The growing middle-class population in these regions, coupled with rising disposable incomes, has significantly improved affordability for medical treatments. As a result, more women are able to access advanced SUI treatment devices, including minimally invasive surgical solutions and non-invasive therapies such as electrical stimulation systems.

For device manufacturers, these developments present lucrative opportunities to expand their footprint in high-potential markets. By establishing local partnerships, investing in region-specific product development, and aligning with government initiatives, companies can effectively address the unique needs of these diverse populations. The increasing adoption of digital health technologies in these regions is further facilitating access to information and treatment, creating a favorable environment for market growth. The combination of improved infrastructure, growing awareness, and economic advancements is transforming emerging markets into critical hubs for the SUI treatment devices market, contributing significantly to its global expansion.

Segmental Insights

Product Type Insights

Based on the Product Type, Among the product types available in the global female stress urinary incontinence (SUI) treatment devices market, urethral slings are currently the dominant segment. Urethral slings are considered the gold standard for surgical intervention in the treatment of moderate to severe stress urinary incontinence. These devices are designed to support the urethra, providing a lifting effect that helps prevent urine leakage during physical activities, such as coughing, sneezing, or exercising. The popularity of urethral slings is driven by their high effectiveness and long-term results compared to other treatment options. One of the key factors contributing to the dominance of urethral slings is their well-established clinical outcomes. Numerous studies and clinical trials have demonstrated their efficacy in providing significant relief from SUI symptoms, leading to widespread adoption by healthcare professionals. The advancement of sling materials, such as synthetic meshes, has improved the safety profile and ease of implantation, further driving their use in clinical practice.

Urethral slings are also favored for their relatively low recurrence rates and the ability to restore normal bladder function, which appeals to both patients and healthcare providers. As a result, they are the first-line surgical treatment recommended for patients with severe cases of stress urinary incontinence who do not respond to conservative measures like pelvic floor exercises or non-invasive devices.

Regional Insights

North America is expected to dominate the global female stress urinary incontinence (SUI) treatment devices market during the forecast period. This dominance is largely driven by the high prevalence of SUI in the region, combined with well-established healthcare infrastructure and significant advancements in medical technologies. In North America, particularly the United States, there is increasing awareness and diagnosis of female SUI, which has led to a growing demand for effective treatment options. The region benefits from a large number of healthcare providers specializing in urology and gynecology, which ensures that patients have access to the latest and most effective treatment devices. Hospitals and ambulatory surgical centers (ASCs) in North America are highly equipped with state-of-the-art medical devices, allowing them to offer a wide range of both non-surgical and surgical SUI treatments, such as urethral slings and electrical stimulation devices.

The high adoption rate of advanced treatment options, especially surgical procedures like sling placements, further drives market growth in the region. North America's relatively high healthcare expenditure, strong reimbursement policies, and favorable regulatory environment for medical devices contribute to the overall market expansion. The rising focus on patient-centric care and the growing shift toward outpatient and minimally invasive procedures also play a key role in propelling market growth.

Key Market Players

Johnson & Johnson
Caldera Medical Inc
B. Braun Medical Limited
Becton, Dickinson and Company
CooperSurgical Inc.
MedGyn Products, Inc
Boston Scientific Corporation
Atlantic Therapeutics
Coloplast Corp.
Convatec Inc.

Report Scope:

In this report, the Global Female Stress Urinary Incontinence Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Stress Urinary Incontinence Treatment Devices Market, By Product Type:

Urethral Slings
Catheters
Vaginal Pessaries
Others

Female Stress Urinary Incontinence Treatment Devices Market, By End-user:

Hospitals & Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Others

Female Stress Urinary Incontinence Treatment Devices Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Stress Urinary Incontinence Treatment Devices Market.

Available Customizations:

Global Female Stress Urinary Incontinence Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Female Stress Urinary Incontinence Treatment Devices Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Urethral Slings, Catheters, Vaginal Pessaries, and Others)
- 5.2.2. By End-user (Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others)
- 5.2.3. By Company (2023)
- 5.2.4. By Region
5.3. Market Map

6. North America Female Stress Urinary Incontinence Treatment Devices Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By End-user
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By End-user
- 6.3.2. Mexico Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By End-user
- 6.3.3. Canada Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By End-user

7. Europe Female Stress Urinary Incontinence Treatment Devices Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By End-user
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By End-user
- 7.3.2. Germany Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By End-user
- 7.3.3. United Kingdom Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By End-user
- 7.3.4. Italy Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By End-user
- 7.3.5. Spain Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By End-user

8. Asia-Pacific Female Stress Urinary Incontinence Treatment Devices Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By End-user
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By End-user
- 8.3.2. India Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By End-user
- 8.3.3. South Korea Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By End-user
- 8.3.4. Japan Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By End-user
- 8.3.5. Australia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By End-user

9. South America Female Stress Urinary Incontinence Treatment Devices Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By End-user
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By End-user
- 9.3.2. Argentina Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By End-user
- 9.3.3. Colombia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By End-user

10. Middle East and Africa Female Stress Urinary Incontinence Treatment Devices Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By End-user
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By End-user
- 10.3.2. Saudi Arabia Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By End-user
- 10.3.3. UAE Female Stress Urinary Incontinence Treatment Devices Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By End-user

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porters Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Johnson & Johnson
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Caldera Medical Inc
14.3. B. Braun Medical Limited
14.4. Becton, Dickinson and Company
14.5. CooperSurgical Inc.
14.6. MedGyn Products, Inc
14.7. Boston Scientific Corporation
14.8. Atlantic Therapeutics
14.9. Coloplast Corp.
14.10. Convatec Inc.